Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses

Expert Review of Vaccines

Volumn 15, Issue 2, 2016, Pages 189-200

  Russell, Charles J ^a,b   Hurwitz, Julia L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

antibody; intranasal; paramyxovirus; pediatric vaccine; respiratory tract; Sendai virus; T cell; vaccine vector

Indexed keywords

HUMAN METAPNEUMOVIRUS VACCINE; HUMAN PARAINFLUENZA VIRUS VACCINE; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; DRUG CARRIER;

CHILDHOOD DISEASE; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; NONHUMAN; PARAMYXOVIRIDAE; PARAMYXOVIRINAE; PARAMYXOVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SENDAI VIRUS; ANIMAL; DRUG DEVELOPMENT; GENE VECTOR; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PARAMYXOVIRIDAE INFECTIONS; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; TRENDS;

ANIMALS; DRUG CARRIERS; DRUG DISCOVERY; GENETIC VECTORS; HUMANS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; SENDAI VIRUS; VIRAL VACCINES;

EID: 84955632844     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1114418     Document Type: Review

References (138)

1. Papers of special note have been highlighted as
2. of interest
3. of considerable interest
4. Nair H, Nokes DJ, Gessner BD., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet. 2010; 375 (9725): 1545-1555
5. Shi T, McLean K, Campbell H., et al. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-Analysis. J Glob Health. 2015; 5 (1): 010408
6. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997; 102 (3A): 2-9; discussion 25-26
7. Lamb RA, Parks GD. Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE. et al., editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 1449-1496
8. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J. 2006; 25 (9): 795-800
9. Edwards KM, Zhu Y, Griffin MR., et al. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368 (7): 633-643
10. Glezen WP, Taber LH, Frank AL., et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986; 140 (6): 543-546
11. Hall CB, Weinberg GA, Iwane MK., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360 (6): 588-598
12. Henrickson KJ. Lower respiratory viral infections in immunocompetent children. Adv Pediatr Infect Dis. 1994; 9: 59-96
13. Shaw CA, Ciarlet M, Cooper BW., et al. The path to an RSV vaccine. Curr Opin Virol. 2013; 3 (3): 332-342
14. Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum Vaccin. 2009; 5 (9): 582-591
15. Marks MI. Respiratory syncytial virus infections. Clin Pediatr. 1992; 31 (11): 688-691
16. Hacimustafaoglu M, Celebi S, Aynaci E., et al. The progression of maternal RSV antibodies in the offspring. Arch Dis Child. 2004; 89 (1): 52-53
17. Shinoff JJ, OBrien KL, Thumar B., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis. 2008; 198 (7): 1007-1015
18. Simoes EA, Groothuis JR, Carbonell-Estrany X., et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007; 151 (1): 34-42
19. Wu H, Pfarr DS, Johnson S., et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007; 368 (3): 652-665
20. Carbonell-Estrany X, Simoes EA, Dagan R., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010; 125 (1): e35-e51
21. Murphy BR, Collins PL. Live-Attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest. 2002; 110 (1): 21-27
22. Ahmed JA, Katz MA, Auko E., et al. Epidemiology of respiratory viral infections in two long-Term refugee camps in Kenya, 2007-2010. BMC Infect Dis. 2012; 12 (7):1-8
23. Weinberg GA, Hall CB, Iwane MK., et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr. 2009; 154 (5): 694-699
24. Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis. 1994; 18 (5): 770-779
25. Groome MJ, Moyes J, Cohen C., et al. Human metapneumovirus-Associated severe acute respiratory illness hospitalisation in HIV-infected and HIV-uninfected South African children and adults. J Clin Virol. 2015; 69: 125-132
26. Srinivasan A, Wang C, Yang J., et al. Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17 (10): 1520-1527
27. Karron RA, Buchholz UJ, Collins PL. Live-Attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013; 372: 259-284
28. Karron RA, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM, Griffin DE. et al., editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 1497-1526
29. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015; 32 (4): 261-269
30. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines. 2011; 10 (10): 1415-1433
31. Rudraraju R, Jones BG, Sealy R., et al. Respiratory syncytial virus: current progress in vaccine development. Viruses. 2013; 5 (2): 577-594
32. Munywoki PK, Koech DC, Agoti CN., et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis. 2014; 209 (11): 1685-1692
33. Anderson LJ, Dormitzer PR, Nokes DJ., et al. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013; 31 (Suppl 2): B209-B215
34. Lambach P, Hombach J, Ortiz JR. A global perspective of maternal influenza immunization. Vaccine. 2015;33:6376-6379
35. Wen SC, Williams JV. New approaches for immunization and therapy against human metapneumovirus. Clin Vaccine Immunol. 2015; 22 (8): 858-866
36. Graham BS, Anderson LJ. Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013; 372: 391-404
37. Anderson LJ. Respiratory syncytial virus vaccine development. Semin Immunol. 2013; 25 (2): 160-171
38. Haynes LM. Progress and challenges in RSV prophylaxis and vaccine development. J Infect Dis. 2013; 208 (Suppl 3): S177-S183
39. Schmidt AC, Schaap-Nutt A, Bartlett EJ., et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med. 2011; 5 (4): 515-526
40. Takimoto T, Hurwitz JL, Zhan X., et al. Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol. 2005; 18 (2): 255-266
41. Chin J, Magoffin RL, Shearer LA., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969; 89 (4): 449-463
42. Fulginiti VA, Eller JJ, Sieber OF., et al. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969; 89: 435-448
43. Beeler JA, Eichelberger MC. Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy. Microb Pathog. 2013; 55: 9-15
44. Power UF, Nguyen TN, Rietveld E., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis. 2001; 184 (11): 1456-1460
45. Choi Y, Mason CS, Jones LP., et al. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 2012; 25 (3): 193-203
46. Piedra PA, Cron SG, Jewell A., et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine. 2003; 21 (19-20): 2448-2460
47. Brideau RJ, Walters RR, Stier MA., et al. Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein. J Gen Virol. 1989; 70: 2637-2644
48. Connors M, Collins PL, Firestone CY., et al. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol. 1991; 65 (3): 1634-1637
49. Power UF, Plotnicky-Gilquin H, Huss T., et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology. 1997; 230 (2): 155-166
50. Dagouassat N, Robillard V, Haeuw JF., et al. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine. 2001; 19 (30): 4143-4152
51. Schepens B, De Baets S, Sedyen K. et al. Meeting presentation: SHes a novel target for RSV vaccination. 8th Respiratory Syncytial Virus Symposium; 2012 Sept 27-30; Santa Fe, NM
52. Morrison TG, Walsh EE. Subunit and virus-like particle vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372: 285-306
53. Glenn GM, Fries LF, Thomas DN., et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2015 Aug 10; pii:jiv406. [Epub ahead of print]
54. Smith G, Raghunandan R, Wu Y., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012; 7 (11): e50852
55. Swanson KA, Settembre EC, Shaw CA., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A. 2011; 108 (23): 9619-9624
56. McLellan JS, Chen M, Leung S., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013; 340 (6136): 1113-1117
57. McLellan JS, Chen M, Chang JS., et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol. 2010; 84 (23): 12236-12244
58. McLellan JS, Yang Y, Graham BS., et al. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85 (15): 7788-7796
59. Loomis RJ, Johnson PR. Gene-based vaccine approaches for respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372: 307-324
60. Yang K, Varga SM. Mucosal vaccines against respiratory syncytial virus. Curr Opin Virol. 2014; 6: 78-84
61. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011; 162 (1-2): 80-99
62. Le Bayon JC, Lina B, Rosa-Calatrava M., et al. Recent developments with live-Attenuated recombinant paramyxovirus vaccines. Rev Med Virol. 2013; 23 (1): 15-34
63. Murawski MR, McGinnes LW, Finberg RW., et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2010; 84 (2): 1110-1123
64. Karron RA, Thumar B, Schappell E., et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine. 2012; 30 (26): 3975-3981
65. Fu YH, He JS, Wang XB., et al. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem Biophys Res Commun. 2010; 395 (1): 87-92
66. Mok H, Lee S, Utley TJ., et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol. 2007; 81 (24): 13710-13722
67. Crowe J, Mok H, Hedgecock J., et al. Alphavirus-based respiratory syncytial virus vaccine induces protection mediated by both humoral and cellular responses, even in the presence of passively-Acquired antibodies. 7th International Respiratory Syncytial Virus Symposium; 2010 Dec 2-5; Rotterdam. p. 142
68. Ishida N, Homma M. Sendai virus. Adv Virus Res. 1978; 23: 349-383
69. Kuroya M, Ishida N. Newborn virus pneumonitis (type Sendai). II. The isolation of a new virus possessing hemagglutinin activity. Yokohama Med Bull. 1953; 4 (4): 217-233
70. Fukumi H, Nishikawa F, Kitayama T. A pneumotropic virus from mice causing hemagglutination. Jpn J Med Sci Biol. 1954; 7 (4): 345-363
71. Parker JC, Whiteman MD, Richter CB. Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents. Infect Immun. 1978; 19 (1): 123-130
72. Bousse T, Chambers RL, Scroggs RA., et al. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res. 2006; 121 (1): 23-32
73. Giorgi C, Blumberg BM, Kolakofsky D. Sendai virus contains overlapping genes expressed from a single mRNA. Cell. 1983; 35 (3 Pt 2): 829-836
74. Curran J, Kolakofsky D. Ribosomal initiation from an ACG codon in the Sendai virus P/C mRNA. EMBO J. 1988; 7 (1): 245-251
75. Vidal S, Curran J, Kolakofsky D. Editing of the Sendai virus P/C mRNA by G insertion occurs during mRNA synthesis via a virus-encoded activity. J Virol. 1990; 64 (1): 239-246
76. Hausmann S, Garcin D, Morel AS., et al. Two nucleotides immediately upstream of the essential A6G3 slippery sequence modulate the pattern of G insertions during Sendai virus mRNA editing. J Virol. 1999; 73 (1): 343-351
77. Lamb RA, Mahy BW, Choppin PW. The synthesis of Sendai virus polypeptides in infected cells. Virology. 1976; 69 (1): 116-131
78. Samal SK, Collins PL. RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. J Virol. 1996; 70 (8): 5075-5082
79. Calain P, Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol. 1993; 67 (8): 4822-4830
80. Kolakofsky D, Pelet T, Garcin D., et al. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol. 1998; 72 (2): 891-899
81. Takimoto T, Bousse T, Coronel EC., et al. Cytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions. J Virol. 1998; 72 (12): 9747-9754
82. Lamb RA, Choppin PW. The synthesis of Sendai virus polypeptides in infected cells. II. Intracellular distribution of polypeptides. Virology. 1977; 81 (2): 371-381
83. Sanderson CM, McQueen NL, Nayak DP. Sendai virus assembly: M protein binds to viral glycoproteins in transit through the secretory pathway. J Virol. 1993; 67 (2): 651-663
84. Sanderson CM, Wu HH, Nayak DP. Sendai virus M protein binds independently to either the F or the HN glycoprotein in vivo. J Virol. 1994; 68 (1): 69-76
85. Heggeness MH, Smith PR, Choppin PW. In vitro assembly of the nonglycosylated membrane protein (M) of Sendai virus. Proc Natl Acad Sci U S A. 1982; 79 (20): 6232-6236
86. Ali A, Nayak DP. Assembly of Sendai virus: M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein. Virology. 2000; 276 (2): 289-303
87. Scheid A, Choppin PW. Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus. Virology. 1974; 57 (2): 475-490
88. Scheid A, Choppin PW. The hemagglutinating and neuraminidase protein of a paramyxovirus: interaction with neuraminic acid in affinity chromatography. Virology. 1974; 62 (1): 125-133
89. Russell CJ, Luque LE. The structural basis of paramyxovirus invasion. Trends Microbiol. 2006; 14 (6): 243-246
90. Russell CJ, Jardetzky TS, Lamb RA. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J. 2001; 20 (15): 4024-4034
91. Lamb RA, Paterson RG, Jardetzky TS. Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology. 2006; 344 (1): 30-37
92. Huang RT, Rott R, Wahn K., et al. The function of the neuraminidase in membrane fusion induced by myxoviruses. Virology. 1980; 107 (2): 313-319
93. Vidal S, Kolakofsky D. Modified model for the switch from Sendai virus transcription to replication. J Virol. 1989; 63 (5): 1951-1958
94. Kato A, Kiyotani K, Hasan MK., et al. Sendai virus gene start signals are not equivalent in reinitiation capacity: moderation at the fusion protein gene. J Virol. 1999; 73 (11): 9237-9246
95. Tokusumi T, Iida A, Hirata T., et al. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res. 2002; 86 (1-2): 33-38
96. Burke CW, Mason JN, Surman SL., et al. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 2011; 7 (7): e1002134
97. Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J. 2008; 27 (10 Suppl): S126-S128
98. Crotty S, Felgner P, Davies H., et al. Cutting edge: long-Term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171 (10): 4969-4973
99. Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev. 2006; 211: 320-337
100. Lyn D, Gill DS, Scroggs RA., et al. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J Gen Virol. 1991; 72: 983-987
101. Dave VP, Allan JE, Slobod KS., et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology. 1994; 199: 376-383
102. Smith FS, Portner A, Leggiadro RJ., et al. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology. 1994; 205 (2): 453-461
103. Sealy R, Jones BG, Surman SL., et al. Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-Type 1. Vaccine. 2010; 28 (41): 6749-6756
104. Rudraraju R, Surman S, Jones B., et al. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-Associated lymphoid tissue typify lymphocyte responses of the gut. Virology. 2011; 410 (2): 429-436
105. Sangster M, Smith FS, Coleclough C., et al. Human parainfluenza virus-Type 1 immunization of infant mice protects from subsequent Sendai virus infection. Virology. 1995; 212: 13-19
106. Hurwitz JL, Soike KF, Sangster MY., et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-Type one. Vaccine. 1997; 15: 533-540
107. Slobod KS, Shenep JL, Lujan-Zilbermann J., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine. 2004; 22 (23-24): 3182-3186
108. Adderson E, Branum K, Sealy RE., et al. Safety and immunogenicity of an intranasal Sendai virus-based parainfluenza virus type 1 vaccine in 3-6 year old children. Clin Vaccine Immunol. 2015;22:298-303
109. Luongo C, Yang L, Winter CC., et al. Codon stabilization analysis of the 248 temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine. 2009; 27 (41): 5667-5676
110. Schickli JH, Kaur J, Tang RS. Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030DeltaSH) at permissive and non-permissive temperatures. Virus Res. 2012; 169 (1): 38-47
111. Henrickson KJ, Kingsbury DW, van Wyke Coelingh KL., et al. Neutralizing epitopes of human parainfluenza virus type 3 are conformational and cannot be imitated by synthetic peptides. Vaccine. 1991; 9: 243-249
112. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996; 14: 369-396
113. Nagai Y, Kato A. Paramyxovirus reverse genetics is coming of age. Microbiol Immunol. 1999; 43 (7): 613-624
114. Sakai Y, Kiyotani K, Fukumura M., et al. Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Lett. 1999; 456 (2): 221-226
115. Kato A, Sakai Y, Shioda T., et al. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells. 1996; 1 (6): 569-579
116. Garcin D, Pelet T, Calain P., et al. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back nondefective interfering virus. EMBO J. 1995; 14 (24): 6087-6094
117. Takimoto T, Hurwitz JL, Coleclough C., et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol. 2004; 78 (11): 6043-6047
118. Zhan X, Hurwitz JL, Krishnamurthy S., et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine. 2007; 25 (52): 8782-8793
119. Zhan X, Slobod KS, Jones BG., et al. Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats. Int Immunol. 2015; 27 (5): 229-236
120. Prince GA, Jenson AB, Hemming VG., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol. 1986; 57 (3): 721-728
121. Jones BG, Sealy RE, Surman SL., et al. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine. 2014; 32 (26): 3264-3273
122. Jones BG, Sealy RE, Rudraraju R., et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine. 2012; 30 (5): 959-968
123. Ishii H, Matano T. Development of an AIDS vaccine using Sendai virus vectors. Vaccine. 2015;33:6061-6065
124. Zhan X, Slobod KS, Krishnamurthy S., et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine. 2008; 26 (27-28): 3480-3488
125. Jones B, Zhan X, Mishin V., et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine. 2009; 27 (12): 1848-1857
126. Brown SA, Surman SL, Sealy R., et al. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses. 2010; 2 (2): 435-467
127. Yu S, Feng X, Shu T., et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine. 2008; 26 (48): 6124-6131
128. Skiadopoulos MH, Surman SR, Riggs JM., et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology. 2002; 297 (1): 153-160
129. Matano T, Kano M, Nakamura H., et al. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol. 2001; 75 (23): 11891-11896
130. Matano T, Kobayashi M, Igarashi H., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med. 2004; 199 (12): 1709-1718
131. Graham BS, Crowe JE Jr. Immunization against viral diseases. In: Knipe DM, Howley PM, Griffin DE. et al., editors. Fields virology. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2007. p. 487-538
132. Lievano F, Galea SA, Thornton M., et al. Measles, mumps, and rubella virus vaccine (M-M-RII): a review of 32 years of clinical and postmarketing experience. Vaccine. 2012; 30 (48): 6918-6926
133. Zachariah P, Stockwell MS. Measles vaccine-past, present and future. J Clin Pharmacol. 2015. 10.1002/jcph.606
134. Jaye A, Magnusen AF, Sadiq AD., et al. Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J Clin Invest. 1998; 102 (11): 1969-1977
135. Chanock RM, Murphy BR, Collins PL. Parainfluenza viruses. In: Knipe DM, Howley PM., editors. Fields virology. Philadelphia (PA): Lippincott Williams and Wilkins; 2001. p. 1341-1379
136. Elliott MB, Pryharski KS, Yu Q., et al. Recombinant respiratory syncytial viruses lacking the C-Terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. J Virol. 2004; 78 (11): 5773-5783
137. Javaherian K, Langlois AJ, Montefiori DC., et al. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J Virol. 1994; 68 (4): 2624-2631
138. Muramatsu M, Homma M. Trypsin action on the growth of Sendai virus in tissue culture cells. V. An activating enzyme for Sendai virus in the chorioallantoic fluid of the embryonated chicken egg. Microbiol Immunol. 1980; 24 (2): 113-122